Emerging biomarkers of prostate cancer (Review)

Martin,Sarah  K.; Vaughan,Taylor  B.; Atkinson,Timothy; Zhu,Haining; Kyprianou,Natasha

doi:10.3892/or.2012.1832

Emerging biomarkers of prostate cancer (Review)

Authors:
- Sarah K. Martin
- Taylor B. Vaughan
- Timothy Atkinson
- Haining Zhu
- Natasha Kyprianou
View Affiliations

Affiliations: Department of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine, Lexington, KY, USA, Division of Urology, Department of Surgery and Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY, USA
Published online on: May 25, 2012 https://doi.org/10.3892/or.2012.1832
Pages: 409-417

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer progression involves activation of signaling pathways controlling cell proliferation, apoptosis, anoikis, angiogenesis and metastasis. The current PSA-based test for the diagnosis of prostate cancer lacks sensitivity and specificity, resulting in missed diagnoses and unnecessary biopsies. Intense research efforts to identify serum and tissue biomarkers will expand the opportunities to understand the functional activation of cancer-related pathways and consequently lead to molecular therapeutic targeting towards inhibition of tumor growth. Current literature describes multiple biomarkers that indicate the properties of prostate cancer including its presence, stage, metastatic potential and prognosis. Used singly, assays detecting these biomarkers have their respective shortcomings. Several recent studies evaluating the clinical utilization of multiple markers show promising results in improving prostate cancer profiling. This review discusses the current understanding of biomarker signature cluster-based approaches for the diagnosis and therapeutic response of prostate cancer derived from panels of biomarker tests that provide a selective molecular signature characteristic of the tumor. As these signatures are robustly defined and their pathways are exhaustively dissected, prostate cancer can be more accurately diagnosed, characterized, staged and targeted with inhibitory antitumor agents. The growing promise surrounding the recent evidence in identifying and utilizing such biomarker panels, will lead to improvement in cancer prognosis and management of the therapeutic response of prostate cancer patients.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar
2	Schröder FH, Hugosson J, Roobol MJ, et al: Screening and prostate cancer mortality in a randomized European study. N Engl J Med. 360:1320–1328. 2009.PubMed/NCBI
3	Fornaro M, Manes T and Languino LR: Integrins and prostate cancer metastases. Cancer Metastasis. 20:321–331. 2001. View Article : Google Scholar : PubMed/NCBI
4	Devlin HL and Mudryj M: Progression of prostate cancer: multiple pathways to androgen independence. Cancer Lett. 274:177–186. 2009. View Article : Google Scholar : PubMed/NCBI
5	US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 149:185–191. 2008. View Article : Google Scholar : PubMed/NCBI
6	Crawford ED and Abrahamsson PA: PSA-based screening for prostate cancer: how does it compare with other cancer screening tests? Eur Urol. 54:262–273. 2008. View Article : Google Scholar
7	McGregor M, Hanley JA, Boivin JF and McLean RG: Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ. 159:1368–1372. 1998.PubMed/NCBI
8	Liu AY, Roudier MP and True LD: Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. Am J Pathol. 165:1543–1556. 2004. View Article : Google Scholar : PubMed/NCBI
9	Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Gorpel M and Tscholl R: Free-to-total prostate specific antigen (PSA) improves the specificity for detecting prostate cancer in patients with prostatism and intermediate PSA levels. Br J Urol. 81:532–538. 1998. View Article : Google Scholar : PubMed/NCBI
10	Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA and Cooner WH: Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 147:815–816. 1992.PubMed/NCBI
11	Catalona WJ, Richie JP, deKernion JB, et al: Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol. 152:2031–2036. 1994.
12	Smith DS and Catalona WJ: Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol. 152:1163–1167. 1994.PubMed/NCBI
13	Lein M, Kwiatkowski M, Semjonow A, et al: A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. J Urol. 170:1175–1179. 2003. View Article : Google Scholar : PubMed/NCBI
14	Mikolajczyk SD and Rittenhouse HG: Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease. Rinsho Byori. 52:223–230. 2004.PubMed/NCBI
15	Seiz L, Kotzsch M, Grebenchtchikov NI, et al: Polyclonal antibodies against kallikrein-related peptidase 4 (KLK4): immunohistochemical assessment of KLK4 expression in healthy tissues and prostate cancer. Biol Chem. 391:391–401. 2010. View Article : Google Scholar
16	Zhou H-J, Yan J, Luo W, et al: SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res. 65:7976–7983. 2005.PubMed/NCBI
17	Fizazi K: The role of Src in prostate cancer. Ann Oncol. 18:1765–1773. 2007. View Article : Google Scholar : PubMed/NCBI
18	Chang CS, Kokontis J and Liao ST: Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors. Proc Natl Acad Sci USA. 85:7211–7215. 1988. View Article : Google Scholar : PubMed/NCBI
19	Hsing AW, Chokkalingam AP, Gao YT, et al: Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population base case control study. Cancer Epidemiol Biomarkers Prev. 11:337–341. 2002.PubMed/NCBI
20	Padmanabhan V, Callas P, Philips G, Trainer TD and Beatty BG: DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer. J Clin Pathol. 57:1057–1062. 2004. View Article : Google Scholar : PubMed/NCBI
21	Dudderidge TJ, Kelly JD, Wollenschlaeger A, et al: Diagnosis of prostate cancer by detection of minichromosome maintenance 5 protein in urine sediments. Br J Cancer. 103:701–707. 2010. View Article : Google Scholar : PubMed/NCBI
22	Rennebeck G, Martelli M and Kyprianou N: Anoikis and survival connections in the tumor microenvironment: is there a role is prostate cancer metastasis? Cancer Res. 65:11230–11235. 2005. View Article : Google Scholar : PubMed/NCBI
23	Kuefer R, Hofer MD, Zorn CS, et al: Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer. Br J Cancer. 92:2018–2023. 2005. View Article : Google Scholar : PubMed/NCBI
24	Tomita K, van Bokhoven A, van Leenders GJ, et al: Cadherin switching in human prostate cancer progression. Cancer Res. 60:3650–3654. 2000.PubMed/NCBI
25	Mao Q, Zheng X, Yang K, et al: Suppression of migration and invasion of PC3 prostate cancer cell line via activating E-cadherin expression by small activating RNA. Cancer Invest. 28:1013–1018. 2010. View Article : Google Scholar : PubMed/NCBI
26	Partin AW, Getzenberg RH and CarMichael MJ: Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res. 53:744–746. 1993.PubMed/NCBI
27	Leman ES, Magheli A, Cannon GW, Mangold L, Partin AW and Getzenberg RH: Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2. Prostate. 69:1188–1194. 2009. View Article : Google Scholar : PubMed/NCBI
28	Shariat SF, Karam JA, Walz J, et al: Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res. 14:3785–3791. 2008. View Article : Google Scholar
29	Malinowska K, Neuwirt H, Cavaretta IT, et al: Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer. 16:155–169. 2009. View Article : Google Scholar : PubMed/NCBI
30	Santer FR, Malinowska K, Culig Z and Cavarretta IT: Interleukin-6 trans-signaling regulates proliferation, migration, adhesion, and maspin expression in human prostate cancer cells. Endocr Relat Cancer. 17:241–253. 2010. View Article : Google Scholar
31	Hessels D, van Gils MP, van Hooij O, Jannink SA, Witjes JA, Verhaegh GW and Schalken JA: Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate. 70:10–16. 2010. View Article : Google Scholar : PubMed/NCBI
32	Groskopf J, Aubin SM, Deras IL, et al: APTIMA PCA3 molecular using test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem. 52:1089–1095. 2006. View Article : Google Scholar : PubMed/NCBI
33	Roobol MJ, Schröder FH, van Leeuwen P, Wolters T, van den Bergh RC, van Leenders GJ and Hessels D: Performance of the prostate cancer antigen 3 (PCA3) gene and prostate specific antigen in prescreen men: exploring the value of PCA3 for a first line diagnostic test. Eur Urol. 58:475–481. 2010. View Article : Google Scholar
34	Helenius MA, Savinainen KJ, Bova GS and Visakorpi T: Amplification of the urokinase gene and the sensitivity of prostate cancer cells to urokinase inhibitor. BJU Int. 97:404–409. 2006. View Article : Google Scholar : PubMed/NCBI
35	Varambally S, Dhanasekaran SM, Zhou M, et al: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 419:624–629. 2002. View Article : Google Scholar : PubMed/NCBI
36	Laitinen S, Martikainen PM, Tolonen T, Isola J, Tammela TL and Visakorpi T: EZH2, Ki-67, and Mcm7 are prognostic markers in prostatectomy treated patients. Int J Cancer. 122:595–602. 2008. View Article : Google Scholar : PubMed/NCBI
37	Li J, Fan QH, Fan XS, Zhou W, Qiu Y and Qiu L: EZH2 expression in human prostate cacner and its clinicopathologic significance. Zhonghua Nan Ke Xue. 16:123–128. 2010.(In Chinese).
38	Yu J, Yu J, Mani RS, et al: An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell. 17:443–454. 2010. View Article : Google Scholar : PubMed/NCBI
39	Yu J, Cao Q, Yu J, et al: The neuronal repellant SLIT2 is a target for repression by EZH2 in prostate cancer. Oncogene. 29:5370–5380. 2010. View Article : Google Scholar : PubMed/NCBI
40	Cao P, Deng Z, Wan M, et al: MicroRNA-101 negtively regulates EZH2 and its expression is modulated by androgen receptor HIF-1α/HIF-1β. Mol Cancer. 9:1082010.PubMed/NCBI
41	Gu Z, Thomas G, Yamashiro J, et al: Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene. 19:1288–1296. 2000. View Article : Google Scholar : PubMed/NCBI
42	Zhao Z, Liu J, Li S and Shen W: Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia. Prostate. 69:1292–1302. 2009. View Article : Google Scholar
43	Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL and Visakorpi T: Amplification and overexpression of androgen receptor gene in hormone refractory prostate cancer. Cancer Res. 61:3550–3555. 2001.PubMed/NCBI
44	Sun S, Sprenger CC, Vessella RL, et al: Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest. 120:2715–2730. 2010. View Article : Google Scholar : PubMed/NCBI
45	Dahlman A, Edsjö A, Halldén C, et al: Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3. Prostate Cancer Prostatic Dis. 13:369–375. 2010. View Article : Google Scholar : PubMed/NCBI
46	Swinnen JV, Roskams T, Joniau S, et al: Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer. 98:19–22. 2002. View Article : Google Scholar : PubMed/NCBI
47	Rossi S, Graner E, Febbo P, et al: Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res. 1:707–715. 2003.PubMed/NCBI
48	Kristiansen G, Fritzsche FR, Wasserman K, et al: GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer. 99:939–948. 2008. View Article : Google Scholar : PubMed/NCBI
49	Laxman B, Morris DS, Yu J, et al: A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 68:645–649. 2008. View Article : Google Scholar : PubMed/NCBI
50	Morgan R, Boxall A, Bhatt A, et al: Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer. Clin Cancer Res. 17:1090–1098. 2011. View Article : Google Scholar : PubMed/NCBI
51	Hermans KG, van Marion R, van Dekken H, Jenster G, van Weerden WM and Trapman J: TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage andgrogen receptor-negative prostate cancer. Cancer Res. 66:10658–10663. 2006. View Article : Google Scholar
52	Perner S, Demichelis F, Beroukhim R, et al: TMPRSS2:ERG fusion associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 66:8337–8341. 2006. View Article : Google Scholar : PubMed/NCBI
53	Soller MJ, Isaksson M, Elfving P, Soller W, Lundgren R and Panagopoulos I: Confirmation of the high frequency of the TMPRSS2:ERG fusion gene in prostate cancer. Genes Chromosomes Cancer. 45:717–719. 2006. View Article : Google Scholar : PubMed/NCBI
54	Nam RK, Sugar L, Wang Z, et al: Expression of TMPRSS2:ERG gene fusions in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther. 6:40–45. 2007. View Article : Google Scholar : PubMed/NCBI
55	Rajput AB, Miller MA, De Luca A, et al: Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol. 60:1238–1243. 2007. View Article : Google Scholar : PubMed/NCBI
56	Tu JJ, Rohan S, Kao J, Kitabayashi N, Mathew S and Chen YT: Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol. 20:921–928. 2007. View Article : Google Scholar
57	Narod SA, Seth A and Nam R: Fusion in the ETS gene family and prostate cancer. Br J Cancer. 99:847–851. 2008. View Article : Google Scholar : PubMed/NCBI
58	Demichelis F, Fall K, Perner S, et al: TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 26:4569–4599. 2007. View Article : Google Scholar : PubMed/NCBI
59	Barwick BG, Abramovitz M, Kodani M, et al: Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts. Br J Cancer. 102:570–576. 2010. View Article : Google Scholar : PubMed/NCBI
60	Stenman UH: SPINK1: a new therapeutic target in cancer? Clin Chem. 57:1474–1475. 2011. View Article : Google Scholar : PubMed/NCBI
61	Goldstein AS, Zong Y and Witte ON: A two step toward personalized therapies for prostate cancer. Sci Transl Med. 3:1–8. 2011. View Article : Google Scholar : PubMed/NCBI
62	Tomlins SA, Rhodes DR, Yu J, et al: The role of SPINK1 in ETS rearrangement negative prostate cancer. Cancer Cell. 13:519–528. 2008. View Article : Google Scholar : PubMed/NCBI
63	Bibikova M, Chudin E, Arsanjani A, et al: Expression signatures that correlated with Gleason score and relapse in prostate cancer. Genomics. 89:666–672. 2007. View Article : Google Scholar : PubMed/NCBI
64	Phé V, Cussenot O and Rouprêt M: Methylated genes as potential biomarkers in prostate cancer. BJU Int. 105:1364–1370. 2010.
65	Woodson K, O’Reilly KJ, Hanson JC, Nelson D, Walk EL and Tangrea JA: The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer. J Urol. 179:508–512. 2008. View Article : Google Scholar : PubMed/NCBI
66	Lou H, Yeager M, Li H, et al: Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc Natl Acad Sci USA. 106:7933–7938. 2009. View Article : Google Scholar : PubMed/NCBI
67	Ahn J, Kibel AS, Park JY, et al: Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence. Clin Cancer Res. 17:1075–1081. 2011. View Article : Google Scholar : PubMed/NCBI